Viatris and Biocon have introduced their interchangeable Semglee insulin glargine biosimilar in the US, along with an unbranded interchangeable version, marking the first ever launch of an interchangeable biosimilar. The non-interchangeable version is expected to be phased out rapidly.
Biosimilars industry stakeholders will finally be able to see the effect of a US interchangeability designation on a product in the marketplace, after Viatris and Biocon launched their Semglee (insulin glargine-yfgn) and unbranded Insulin Glargine biosimilars in the US.
“Both biosimilar products are available in vial and pre-filled pen presentations and are interchangeable for the reference brand, Lantus, allowing...
There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.
After acquiring a solid biosimilars business from Viatris, Biocon Biologics has ticked off another market for its Nepexto (etanercept).
At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.
Generics Bulletin reviews global regulatory developments across the world.
At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.
Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.
Generics Bulletin reviews global regulatory developments across the world.
